NASDAQ:PAHC News 6 February 2026

February 6, 2026, 1:07 PM EST. Regeneron Pharmaceuticals (REGN) has experienced a recent pullback, with its share price falling about 1% in one day and 5.6% over the past month. Yet, the stock maintains a 16.6% gain over three months and a strong 58.7% total return over five years. Trading near $766.63, REGN is valued below the fair value estimate of $821 per share, based on expected revenue growth, firm margins, and pipeline progress in immunology, oncology, and genetic medicines. Analysts highlight Regeneron's solid pipeline, including advances in Lynozyfic and odronextamab, suggesting potential earnings upside backed by demographic demand and precision medicine trends. The stock's discount may reflect market expectations, but the 7% discount rate and anticipated share count reductions support a cautiously optimistic outlook for investors.